Study Of AIDS Statistics Hinges On Debate Over Methods, Politics

WASHINGTON—At the National Center for Health Statistics in Hyattsville, Md., James Massey and his colleagues are holding their breath and waiting with fingers crossed for word from Dallas. Starting Sept. 26, researchers will be knocking on doors to collect blood samples and information about possible risk behaviors for AIDS from 1,600 Texans. The results of this pilot study will determine the future of the National Household Seroprevalence Survey, a planned $25 million project to canva

Written byElizabeth Pennisi
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

WASHINGTON—At the National Center for Health Statistics in Hyattsville, Md., James Massey and his colleagues are holding their breath and waiting with fingers crossed for word from Dallas. Starting Sept. 26, researchers will be knocking on doors to collect blood samples and information about possible risk behaviors for AIDS from 1,600 Texans. The results of this pilot study will determine the future of the National Household Seroprevalence Survey, a planned $25 million project to canvass U.S. neighborhoods in an effort to provide the nation’s best estimate of who may develop AIDS.

“If we have a failure in Dallas, it will mean the end of the survey,” says Massey, chief of survey design at the center. He is not the only one keeping a close eye on this project. During the past five years, statistical and mathematical experts used to working backstage are finding themselves blinded by the AIDS spotlight. They ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies